Rapamycin (Sirolimus) Dosing in Hepatic Impairment

What Sirolimus Is and How It Works

Sirolimus is a macrolide produced by Streptomyces hygroscopicus that inhibits the mechanistic target of rapamycin complex 1 (mTORC1) by binding the intracellular chaperone FKBP12 [1]. The FKBP12-sirolimus complex then binds mTORC1 directly, blocking downstream phosphorylation of S6 kinase 1 and 4E-BP1. That single step suppresses T-cell proliferation (the transplant rationale) and reduces anabolic signaling associated with cellular aging (the longevity rationale) [2].

mTORC1 vs mTORC2

At standard doses, sirolimus spares mTORC2, which governs glucose metabolism and Akt phosphorylation. Prolonged high-dose exposure may attenuate mTORC2 as well, a difference that partially explains the metabolic side-effect profile seen at transplant doses versus the lower weekly doses used in longevity protocols [2].

Approved and Off-Label Uses

The FDA approved sirolimus in 1999 for kidney transplant rejection prophylaxis [3]. Off-label applications include lymphangioleiomyomatosis (now with its own FDA label for everolimus), vascular anomalies, and, increasingly, anti-aging or longevity protocols. The PEARL trial (Aging Cell 2024, N=114) is among the first randomized controlled data examining sirolimus in healthy older adults outside a transplant setting [4].

Sirolimus Pharmacokinetics: The Liver's Central Role

The liver is the primary site of sirolimus metabolism. Understanding normal hepatic PK is the prerequisite for adjusting doses when that function is impaired.

Absorption and Bioavailability

Oral bioavailability averages about 15% for the tablet formulation and 14% for the oral solution, partly because intestinal CYP3A4 and P-glycoprotein (P-gp) extract a large fraction before systemic circulation [5]. A high-fat meal increases the tablet AUC by roughly 35%; patients should take sirolimus consistently with or without food at each dose to minimize variability [3].

Distribution and Protein Binding

Sirolimus has an extremely large volume of distribution, approximately 12 L/kg, owing to extensive partitioning into red blood cells (hematocrit-dependent) and high protein binding (~92%) to albumin and alpha-1-acid glycoprotein [5]. In liver disease, both albumin and hematocrit frequently fall, shifting the free fraction upward and amplifying exposure beyond what whole-blood trough levels alone may indicate.

Hepatic Metabolism and Elimination

CYP3A4 in the liver and gut wall is responsible for seven identified metabolites of sirolimus, including the major hydroxy-, demethyl-, and hydroxydemethyl-sirolimus species [3]. The mean whole-blood half-life is approximately 62 hours in subjects with normal hepatic function [3]. Roughly 91% of an administered dose is eliminated in feces; renal excretion accounts for only about 2.2% [3].

How Hepatic Impairment Alters Sirolimus Exposure

Liver disease disrupts sirolimus PK through at least three simultaneous mechanisms: reduced CYP3A4 enzymatic capacity, decreased P-gp efflux, and altered protein binding. The net effect is higher, more variable whole-blood concentrations for a given dose.

Pharmacokinetic Data from the FDA Label and Primary Studies

The FDA-approved prescribing information for Rapamune reports a dedicated hepatic-impairment study [3]. Compared with healthy controls, subjects with mild hepatic impairment (Child-Pugh class A) showed a 43% increase in sirolimus AUC. Moderate impairment (Child-Pugh B) produced a 94% increase. The half-life extended from ~62 hours in controls to approximately 73 hours in mild and 113 hours in severe impairment [3].

A pharmacokinetic analysis published in Clinical Pharmacokinetics confirmed that Child-Pugh score is a stronger predictor of sirolimus clearance than serum bilirubin alone, because the score incorporates albumin, prothrombin time, and encephalopathy grade, all of which reflect hepatocyte mass [6].

Why Troughs Underestimate True Exposure in Cirrhosis

In patients with cirrhosis, the hematocrit often falls below 30%, reducing red-blood-cell partitioning. Because whole-blood trough measurement depends on that partitioning, a cirrhotic patient may have a "normal" trough of 8 ng/mL yet carry substantially higher free-drug plasma concentrations than a transplant recipient with a hematocrit of 42% and the same reported trough [6]. Clinicians should factor the patient's hematocrit into trough interpretation.

FDA-Recommended Dose Adjustments by Severity

The current FDA label provides explicit maintenance-dose guidance stratified by Child-Pugh class [3].

Mild Impairment (Child-Pugh A)

Reduce the maintenance dose by approximately one-third. A patient on 2 mg/day for transplant prophylaxis would move to approximately 1.3 mg/day, practically rounded to 1 mg/day or guided by trough concentrations. The loading dose (15 mg for de novo transplant) is not changed because loading-dose PK is driven more by distribution volume than by clearance [3].

Moderate Impairment (Child-Pugh B)

Reduce the maintenance dose by approximately one-half. Trough monitoring every five to seven days is mandatory until three consecutive levels fall within the target range. A patient converting from calcineurin inhibitor therapy who normally targets 12 to 20 ng/mL should accept a lower provisional target (10 to 15 ng/mL) while dose-finding proceeds [3].

Severe Impairment (Child-Pugh C)

The FDA label recommends a reduction of approximately two-thirds from the standard maintenance dose, with individualization guided by trough monitoring [3]. The safety profile in Child-Pugh C patients is not well characterized in prospective trials; most published data come from case series. Clinicians should treat this population with caution, choosing the lowest effective trough target and monitoring for mTOR-related toxicities: thrombocytopenia, hypertriglyceridemia, impaired wound healing, and pulmonary toxicity [3].

Trough Monitoring: Targets, Timing, and Interpretation

Whole-blood sirolimus trough concentration is the standard pharmacodynamic surrogate for both efficacy and toxicity [7].

Transplant Trough Targets

Per the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guidelines, acceptable trough ranges depend on time post-transplant and co-immunosuppression [7]:

• Months 1 to 3 with calcineurin inhibitor combination: 4 to 12 ng/mL
• After calcineurin inhibitor withdrawal (months 3 to 6): 12 to 20 ng/mL
• Long-term maintenance monotherapy: 12 to 20 ng/mL

In hepatic impairment, these targets remain the clinical goal, but the dose needed to reach them will be substantially lower than in patients with normal liver function.

Off-Label Longevity Trough Targets

No consensus trough range exists for longevity use. The PEARL trial tested 5 mg weekly and 10 mg bi-weekly regimens in adults aged 50 to 85 years (N=114) and measured immune-function endpoints rather than pharmacokinetic targets [4]. Participants reported improved self-rated health at 16 weeks compared with placebo (P<0.05) [4]. The trial excluded patients with hepatic disease, leaving a gap in safety and PK data for longevity-use patients with liver dysfunction.

Monitoring Frequency in Liver Disease

The following schedule applies to transplant recipients with hepatic impairment; clinicians adapting it for off-label use should apply the same principles:

1. Check trough 5 to 7 days after any dose change.
2. Repeat every 5 to 7 days until three consecutive values are within target.
3. Once stable, monitor monthly for the first year, then every three months.
4. Re-initiate intensive monitoring if liver function tests change by more than one Child-Pugh point.

Drug Interactions That Compound Hepatic-Impairment Risk

Sirolimus is highly susceptible to drug interactions because it is both a CYP3A4 substrate and a mild P-gp inhibitor [3]. Hepatic impairment compounds this problem in two ways: baseline clearance is already reduced, and patients with liver disease frequently take medications that further inhibit CYP3A4.

Strong CYP3A4 Inhibitors

Ketoconazole increased sirolimus Cmax by 4.3-fold and AUC by 10.9-fold in a dedicated interaction study [3]. Voriconazole, clarithromycin, erythromycin, and ritonavir carry similar interaction magnitude. In a hepatically impaired patient, co-prescribing any of these agents without dramatic dose reduction risks life-threatening toxicity.

Strong CYP3A4 Inducers

Rifampicin decreased sirolimus AUC by approximately 82% in healthy volunteers [3]. A hepatically impaired patient stopping rifampicin therapy may experience a sudden two- to five-fold rise in sirolimus exposure, requiring close trough monitoring during and after the induction period.

Calcineurin Inhibitor Co-Administration

Cyclosporine itself is a moderate CYP3A4 inhibitor. In the standard transplant regimen, cyclosporine increases sirolimus AUC by roughly 1.8-fold, which is why transplant protocols give sirolimus four hours after cyclosporine [3]. In a patient with Child-Pugh B disease receiving both drugs, the combined PK effect may produce troughs double or triple the target even at low doses.

Hepatotoxicity Risk: Is Sirolimus Safe in Liver Disease?

The question of whether sirolimus itself causes liver injury is clinically distinct from the question of how liver disease changes its PK.

Hepatic Artery Thrombosis

In liver-transplant recipients, sirolimus carries an FDA black-box warning for increased hepatic artery thrombosis risk when used for rejection prophylaxis [3]. The FDA label states: "The use of sirolimus in combination with tacrolimus was associated with excess mortality and graft loss." This warning applies specifically to liver transplant and does not apply to kidney transplant or off-label longevity use.

Cholesterol and Triglyceride Elevation

Sirolimus inhibits mTORC1-mediated lipid catabolism, raising LDL by a mean of 0.5 to 1.0 mmol/L and triglycerides by a mean of 1.0 to 2.5 mmol/L in transplant trials [8]. In patients with non-alcoholic fatty liver disease (NAFLD) or alcoholic liver disease, where dyslipidemia may already be severe, statin therapy should be initiated proactively rather than reactively.

Direct Hepatotoxicity

Sirolimus-associated drug-induced liver injury (DILI) has been reported in case reports and a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS), but confirmed hepatocellular injury attributable to sirolimus as a sole agent is uncommon [9]. The more common pattern is mild transaminase elevation that resolves with dose reduction.

Longevity Protocols and the Missing Hepatic-Impairment Data

The off-label use of sirolimus for longevity has accelerated since 2023, driven partly by preclinical lifespan extension data in mice and partly by emerging human trials.

PEARL Trial (2024)

PEARL (N=114, Aging Cell 2024) randomized healthy adults aged 50 to 85 to placebo, sirolimus 5 mg weekly, or sirolimus 10 mg bi-weekly for 16 weeks [4]. The primary outcome was self-reported health measured by the PROMIS Global Health questionnaire. Participants on sirolimus 5 mg weekly reported a statistically significant improvement in global health score versus placebo (P<0.05) [4]. The trial excluded participants with hepatic disease, elevated transaminases more than twice the upper limit of normal, or known cirrhosis. The longevity-use community therefore has no randomized PK or safety data for hepatically impaired patients.

ITP Program Mouse Data

The Interventions Testing Program (ITP), coordinated by the National Institute on Aging, showed that rapamycin extended median lifespan in genetically heterogeneous mice by 9 to 14% when initiated at 600 days of age (roughly equivalent to middle age in humans) [10]. Translating that finding to hepatically impaired humans requires extrapolation across species, dose, formulation, and now organ function, none of which have been studied in combination.

Practical Guidance for Off-Label Use in Patients With Liver Disease

Physicians considering sirolimus for longevity indications in patients with Child-Pugh A or B disease should apply the FDA-labeled maintenance-dose reductions as the starting framework, check a baseline whole-blood trough at day 7, and titrate slowly. A starting dose of 1 mg weekly (rather than the typical 5 mg) in a Child-Pugh A patient is a reasonable, conservative opening position. Patients with Child-Pugh C disease should not receive sirolimus outside a closely monitored research protocol.

Practical Prescribing Checklist for Hepatic Impairment

Before initiating sirolimus in any patient with known or suspected liver disease, a prescriber should complete the following steps:

1. Assign Child-Pugh class using current labs (bilirubin, albumin, INR, ascites grade, encephalopathy grade).
2. Review the full medication list for CYP3A4 inhibitors and inducers.
3. Apply the maintenance-dose reduction table from the FDA label [3].
4. Order baseline whole-blood sirolimus trough, CBC, lipid panel, and hepatic function panel.
5. Set a 5 to 7-day follow-up trough after the first dose.
6. Inform the patient that consistent food intake at each dose matters for predictable absorption.
7. Document the rationale for off-label use and the dose-adjustment reasoning in the clinical note.